TG Therapeutics | TGTX - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Alaunos Therapeutics USD 1.88M 1.08M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Ardelyx USD 504.51M 2.9M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
Biogen USD 32.09B 2.6B 2026-06
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Curis USD 19.97M 9.27M 2025-12
Gilead Sciences USD 56.28B 2.74B 2026-03
J&J USD 201.06B 167M 2026-06
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Novartis USD 122.03B 3.5B 2026-06
Novavax USD 1.04B 133.35M 2026-03
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
TG Therapeutics USD 1.53B 465.58M 2026-03
Verastem USD 246.44M 69.59M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03